What does Galectin Therapeutics Inc. do?
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced…
What is Galectin Therapeutics Inc.'s P/E and P/B ratio?
Galectin Therapeutics Inc. has a P/E ratio of -7.9 and a P/B ratio of -2.49.
What is Galectin Therapeutics Inc.'s debt-to-equity ratio?
Galectin Therapeutics Inc. has a debt-to-equity ratio of -1.06.
How much does Galectin Therapeutics Inc. owe compared with what it owns?
Galectin Therapeutics Inc. owes $10.2 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is Galectin Therapeutics Inc.'s Positivity rank?
Galectin Therapeutics Inc. is ranked #6,397 of 6,774 companies globally and #3,663 of 4,000 in United States on PositoAI, with a Positivity Score of -18,572.
Does Galectin Therapeutics Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Galectin Therapeutics Inc..
Where can I read the latest news about Galectin Therapeutics Inc.?
Recent headlines about Galectin Therapeutics Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Galectin Therapeutics Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Galectin Therapeutics Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.